Skip to main content

Features of Japanese patients with myelodysplastic syndrome in an aging population of Sado Island

International Journal of Hematology volume 95, pages 420–427 (2012)Cite this article

Abstract

Myelodysplastic syndrome (MDS) is relatively common in the elderly, and aging of populations is progressing in developed nations, notably so in Japan. The major age group in Japan and Sado Island are distributed between 30 and 60 and between 50 and 80, respectively. The aim of this study was to analyze the features of MDS in the population of Sado Island to anticipate the characteristics of the disease in the near future. One-hundred and fifty-three patients (71 male, 82 female, 19–94 years old, median 73 years old) with de novo MDS between 1985 and 2005 were retrospectively evaluated. All patients were reclassified according to WHO-2001 criteria. The predictive power of the international prognostic scoring system and the WHO classification-based prognostic scoring system were evaluated. The major causes of death were leukemic transformation (38%) in refractory anemia with an excess of blasts and infection (48%) for total MDS. Age was another independent prognostic factor. Elderly patients exhibited a significantly poorer prognosis mainly due to infections such as pneumonia. Although novel remedies for MDS and hyperferremia have recently been developed, prevention of infection remains important in MDS, particularly for older patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.

    PubMed  CAS  Google Scholar 

  2. Jaffe WS, Harris NL, Stein H. World Health Organization Classification of Tumors. Pathology and genetics, tumor of haematopoietic and lymphoid tissues. IARC Press, Lyon, 2001.

  3. Swerdlow SH, Campo E, Harris NL. WHO Classification of tumours of heamatopoietic and lymphoid tissues. Lyon: IARC Press; 2008.

    Google Scholar 

  4. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;91:2079–88.

    Google Scholar 

  5. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503–10.

    PubMed  Article  Google Scholar 

  6. Iwanaga M, Hsu WL, Soda M, Takasaki Y, Tawara M, Joh T, et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol. 2011;29:428–34.

    PubMed  Article  Google Scholar 

  7. Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood. 2005;106:2633–40.

    PubMed  Article  CAS  Google Scholar 

  8. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385–95.

    PubMed  Article  CAS  Google Scholar 

  9. Tasaka T, Tohyama K, Kishimoto M, Ohyashiki K, Mitani K, Hotta T, et al. Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan. Leukemia. 2008;22:1874–81.

    PubMed  Article  CAS  Google Scholar 

  10. Li L, Liu XP, Nie L, Yu MH, Zhang Y, Qin TJ, et al. Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients. Leuk Res. 2009;33(9):1194–8.

    PubMed  Article  Google Scholar 

  11. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndrome. Br J Haematol. 1994;87:743–5.

    PubMed  Article  CAS  Google Scholar 

  12. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992;82:358–67.

    PubMed  Article  CAS  Google Scholar 

  13. Rådlund A, Thiede T, Hansen S, Carlsson M, Engquist L. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol. 1995;54:153–6.

    PubMed  Article  Google Scholar 

  14. Maynadié M, Verret C, Moskovtchenko P, Mugneret F, Petrella T, Caillot D, et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer. 1996;74:288–90.

    PubMed  Article  Google Scholar 

  15. Oguma S, Yoshida Y, Uchino H, Maekawa T, Nomura T, Mizoguchi H. Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Anemia Study Group of the Ministry of Health and Welfare. Leuk Res. 1995;19:219–25.

    PubMed  Article  CAS  Google Scholar 

  16. Oguma S, Yoshida Y, Okuma M, Uchino H, Maekawa T, Nomura T, et al. Mode of disease progression in primary myelodysplastic syndromes: a Japanese co-operative study. The Refractory Anemia Study Group of The Ministry of Health and Welfare, Japan. Leuk Res. 1997;21:241–7.

    PubMed  Article  CAS  Google Scholar 

  17. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010;116:2174–9.

    PubMed  Google Scholar 

  18. Kantarjian H, O’Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351–61.

    PubMed  Article  CAS  Google Scholar 

  19. Nösslinger T, Tüchler H, Germing U, Sperr WR, Krieger O, Haase D, et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol. 2010;21:120–5.

    PubMed  Article  Google Scholar 

  20. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res. 2000;24:983–92.

    PubMed  Article  CAS  Google Scholar 

  21. Pomeroy C, Oken MM, Rydell RE, Filice GA. Infection in the myelodysplastic syndromes. Am J Med. 1991;90:338–44.

    PubMed  CAS  Google Scholar 

  22. Lee JH, Lee KH, Lee JH, Kim DY, Kim SH, Lim SN, et al. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome. Leuk Res. 2011;35:499–503.

    PubMed  Article  CAS  Google Scholar 

  23. Horiike S, Yokota S, Nakao M, Iwai T, Sasai Y, Kaneko H, et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia. 1997;11:1442–6.

    PubMed  Article  CAS  Google Scholar 

  24. Kita-Sasai Y, Horiike S, Misawa S, Kaneko H, Kobayashi M, Nakao M, et al. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br J Haematol. 2001;115:309–12.

    PubMed  Article  CAS  Google Scholar 

  25. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature. 1974;251:437–8.

    PubMed  Article  Google Scholar 

  26. Park MJ, Kim HJ, Kim SH, Kim DH, Kim SJ, Jang JH, et al. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Eur J Haematol. 2008;81:364–73.

    PubMed  Google Scholar 

  27. Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res. 2007;31(Suppl 3):S7–9.

    PubMed  Article  CAS  Google Scholar 

  28. Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res. 2010;34:864–70.

    PubMed  Article  CAS  Google Scholar 

  29. Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27:754–62.

    PubMed  Article  Google Scholar 

  30. Breccia M, Federico V, Latagliata R, Mercanti C, D’Elia GM, Cannella L, et al. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. Leuk Res. 2011;35:159–62.

    PubMed  Article  Google Scholar 

  31. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato LN, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica. 2002;87:1286–306.

    PubMed  Google Scholar 

  32. Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003;120:187–200.

    PubMed  Article  Google Scholar 

  33. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–65.

    PubMed  Article  CAS  Google Scholar 

  34. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111:86–93.

    PubMed  Article  CAS  Google Scholar 

  35. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32.

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgments

We greatly appreciate the assistance of Masae Honma of the Clinical Laboratory of Sado Sogo Hospital for her management of clinical samples and data.

Conflict of interest

No conflict of interest.

Author information

Affiliations

  1. Department of Internal Medicine, Sado Sogo Hospital, Niigata, Japan

    Kumiko Yagisawa, Masaru Urushiyama, Noriko Izumi, Akira Hattori & Ken Momotsu

  2. First Department of Internal Medicine, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan

    Kiyoshi Okazuka, Ken Toba, Takashi Kuroha, Yasuhiko Sibasaki, Masutaka Higashimura, Toshio Yano, Akihito Momoi & Yoshifusa Aizawa

Authors
  1. Kumiko Yagisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kiyoshi Okazuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ken Toba
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masaru Urushiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takashi Kuroha
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Noriko Izumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasuhiko Sibasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masutaka Higashimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Toshio Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Akihito Momoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Akira Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ken Momotsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yoshifusa Aizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ken Toba.

About this article

Cite this article

Yagisawa, K., Okazuka, K., Toba, K. et al. Features of Japanese patients with myelodysplastic syndrome in an aging population of Sado Island. Int J Hematol 95, 420–427 (2012). https://doi.org/10.1007/s12185-012-1031-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-012-1031-z

Keywords

  • Myelodysplastic syndrome
  • Aging society
  • Prognosis
  • Infection prevention